Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Download Sample Pdf
MARKET INSIGHTS
The global Plasma Collection Machines (PCM) market was valued at USD 354 million in 2024 and is projected to reach USD 448 million by 2031, exhibiting a CAGR of 3.5% during the forecast period. This growth is primarily driven by increasing demand for plasma-derived therapies, rising geriatric populations requiring plasma treatments, and expansion of healthcare infrastructure in emerging markets.
Plasma Collection Machines (PCM) are specialized medical devices designed for the safe and efficient collection of blood plasma from donors. These systems utilize advanced apheresis technology to separate plasma from other blood components, enabling collection of 600-800mL of plasma per session while maintaining donor safety. The global market is dominated by automated systems offering integrated donor management, real-time monitoring, and compliance with regulatory standards like FDA and EMA guidelines.
The market growth is further accelerated by several key factors: increasing global demand for immunoglobulins (expected to reach USD 25.4 billion by 2028), growing adoption of plasma-derived therapies for neurological and autoimmune disorders, and technological advancements in apheresis equipment that reduce procedure time to 45-60 minutes. However, market growth faces constraints from high equipment costs (ranging USD 150,000-350,000 per unit) and stringent regulatory requirements across different regions.
Geographically, North America holds the largest market share (42%) due to well-established plasma collection infrastructure and high plasma utilization rates (over 40 million liters collected annually in the U.S. alone). Europe follows with 28% market share, driven by increasing immunoglobulin demand and government initiatives supporting plasma collection. The Asia-Pacific region shows the highest growth potential (CAGR 6.2%) due to increasing healthcare investments and rising plasma therapy awareness.
Rising Global Demand for Plasma-Derived Therapies
The global market for plasma-derived therapies is experiencing significant growth, driven by increasing demand for immunoglobulins, albumin, and other plasma products. This demand is particularly strong in both developed and emerging markets as healthcare infrastructure improves.
Advancements in Apheresis Technology
Modern plasma collection machines have become more efficient and patient-friendly, with reduced procedure times and improved donor comfort. These technological advancements are driving increased adoption across collection facilities.
The global plasma market is projected to reach $44.7 billion by 2028, growing at a CAGR of 6.8%
Growing awareness of plasma's therapeutic applications and the expansion of plasma collection networks in developing countries are creating new growth vectors for the industry.
MARKET CHALLENGES
High Operational Costs and Infrastructure Requirements
Establishing and maintaining plasma collection centers requires significant investment in both equipment and trained personnel. The cost of plasma collection machines themselves ranges from $50,000 to $150,000 per unit, creating barriers for smaller operators.
Other Challenges
Regulatory Compliance and Quality Assurance
Plasma collection is heavily regulated in most markets, with requirements for donor screening, testing, and documentation creating administrative burdens. Compliance with evolving regulations requires continuous investment in training and quality systems.
Limited Donor Base and Eligibility Criteria
Stringent donor eligibility criteria significantly restrict the potential donor pool. Approximately 38% of the general population is ineligible to donate plasma due to medical, travel, or lifestyle factors, creating a natural limitation on supply expansion.
Emerging Markets and Infrastructure Development
As healthcare infrastructure improves in developing economies, the demand for plasma-derived medicines is creating new markets. Countries with large populations are establishing national plasma programs, creating opportunities for equipment manufacturers and service providers.
The global shift toward personalized medicine is creating demand for specialized plasma products, driving innovation in collection technologies. The market for hyperimmune globulins and other specialized plasma products is expected to grow at 12.3% annually through 2030.
| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
Automated Apheresis Machines dominate due to superior efficiency, reduced operator error, and integrated quality control systems that ensure consistent plasma collection with minimal manual intervention. |
| By Application |
|
Source Plasma Collection remains pivotal due to growing global demand for plasma-derived therapies, increasing donor populations, and expansion of collection networks into emerging markets. |
| By End User |
|
Plasma Collection Centers lead due to specialized infrastructure, high-volume processing capabilities, and established donor management systems that optimize collection efficiency. |
Companies Strive to Strengthen their Product Portfolio to Sustain Competition
Haemonetics Corporation (USA) leads the plasma collection market with its advanced apheresis systems, maintaining approximately 35% market share through strategic partnerships with major plasma collection networks and continuous R&D investment in automation technologies.
Fresenius Kabi AG (Germany) follows as a strong second, leveraging its global distribution network and comprehensive blood management portfolio to capture key European and Asian markets through integrated solutions.
Terumo BCT, Inc. (Japan/USA) focuses on technological innovation with its latest Trima Accel system, targeting automated efficiency and reduced procedure times to compete in high-growth Asian markets.
CSL Limited (Australia), primarily known for plasma-derived therapies, vertically integrated into collection technology with its own plasma collection systems, creating synergistic revenue streams.
Grifols, S.A. (Spain) maintains significant market presence through its plasma collection centers and proprietary technology, focusing on integrated solutions.
List of Key Plasma Collection Equipment Companies ProfiledHaemonetics Corporation (USA)
Fresenius Kabi AG (Germany)
Terumo BCT, Inc. (Japan/USA)
CSL Limited (Australia)
Grifols, S.A. (Spain)
Octapharma Plasma (USA)
Shandong Zhongbaotong Automation Group (China)
The global plasma collection market is experiencing significant growth, driven by rising demand for immunoglobulins, albumin, and other plasma-derived therapies. With aging populations and increasing prevalence of immune disorders, plasma collection volumes have increased by approximately 8-10% annually over the past three years. This growth is particularly pronounced in North America and Europe, where plasma collection centers are expanding their operations and adopting newer, more efficient PCM technologies.
Other TrendsTechnological Advancements in Collection Systems
Modern plasma collection machines now incorporate advanced automation and safety features, including improved vein detection, automated needle insertion, and enhanced separation technologies. These advancements have reduced collection times by approximately 25% while improving donor comfort and safety. The market has also seen increased adoption of double-needle systems that enable simultaneous collection from multiple donors, significantly increasing center throughput.
The plasma collection industry is experiencing consolidation as larger players acquire independent collection centers to secure plasma supply. Regulatory bodies are implementing stricter quality control measures, with the FDA and EMA introducing new guidelines for pathogen reduction technologies that must be integrated into PCM systems. This has led to increased R&D investment in pathogen inactivation systems, which now account for approximately 15-20% of total equipment costs.
The plasma collection market is projected to reach $XX billion by 2028, growing at a CAGR of 9.2%. Growth is particularly strong in emerging markets where healthcare infrastructure development is driving increased plasma collection capacity. The Asia-Pacific region shows the highest growth rate at 12.3% annually, driven by increasing healthcare expenditure and growing awareness of plasma-derived therapies.
Regional Analysis: Plasma Collection Machines (PCM) MarketEurope
European markets maintain strong PCM adoption through integrated health systems and established regulatory pathways. The region shows particular strength in automated collection systems, with Germany and Switzerland hosting major equipment manufacturers. European operators prioritize data integration, remote monitoring, and compliance with evolving EU medical device regulations. Markets remain relatively saturated but continue gradual growth through replacement cycles and upgrades to newer generation equipment with enhanced donor comfort features and connectivity.
Asia-Pacific
Asia-Pacific represents the growth engine for PCM markets, with China's plasma collection infrastructure expanding at over 15% annually. Countries implement national self-sufficiency programs while increasing international collaboration. India and Southeast Asian markets focus on affordable, high-volume collection systems with simplified interfaces. South Korea and Japan lead in automation and robotics integration, while Australia shows strong per-capita collection rates through public-private initiatives. The region drives innovation in mobile collection units and integrated diagnostic systems.
Latin America
Latin American markets show robust growth through integrated health system development and increasing plasma therapy adoption. Brazil remains the regional leader with extensive collection networks and growing domestic production. Mexico shows strong growth in border regions with U.S. collaboration. Argentina and Chile develop specialized collection centers serving both domestic needs and clinical research markets. The region benefits from geographic proximity to North American manufacturers while developing local manufacturing capabilities for collection equipment and consumables.
Middle East & Africa
Middle Eastern markets focus on high-value plasma collection through specialty centers and medical tourism infrastructure. Gulf states invest in state-of-the-art collection facilities while North African countries develop more generalized collection networks. Sub-Saharan Africa shows emerging potential through international health initiatives and growing recognition of plasma-derived therapies. The region shows increasing adoption of automated collection systems with emphasis on robust, temperature-controlled equipment suitable for varied operational environments.
The report provides an in-depth analysis of the global Plasma Collection Machines (PCM) market, covering market size, growth trends, competitive landscape, and key regional markets. It serves as a comprehensive guide for stakeholders in the healthcare and medical devices industry.
This market research report offers a holistic overview of the global and regional markets for the forecast period 2025-2032. It presents accurate and actionable insights based on a blend of primary and secondary research.
✅ Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
✅ Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
✅ Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
✅ Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
✅ Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
✅ Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
✅ Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
✅ Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Pharmaceutical and biotech companies
Medical device and diagnostics manufacturers
Healthcare providers and hospital systems
Contract research and manufacturing organizations
Investors, consultants, and policy makers
-> The global Plasma Collection Machines market was valued at USD 354 million in 2024 and is expected to reach USD 448 million by 2031.
-> Key players include Terumo BCT, Fresenius Kabi, Haemonetics, Asahi Kasei Medical, Nikkiso, B. Braun, Miltenyi Biotec, Kaneka Medix, Nigale, Haier Biomedical, Scinomed, Medica SPA, Shanghai Dahua Medical Equipment, among others.
-> Key growth drivers include increasing demand for plasma-derived therapies, aging population requiring plasma treatments, expansion of healthcare infrastructure in emerging markets, and technological advancements in apheresis equipment.
-> North America holds the largest market share (42%) due to well-established plasma collection infrastructure and high plasma utilization rates. Europe follows with 28% market share, driven by increasing immunoglobulin demand and government support.
-> Emerging trends include automation of collection processes, integration of AI for donor management, development of more efficient and safer collection systems, and increasing focus on pathogen-reduced plasma products.
Our Clients
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates